Largest Biopharmaceutical Classes (Sales figures are worldwide for 2006.) 01* EPO $11.9B (Aranesp, Epogen, Procrit, NeoRecormon) 02. Cancer mAbs $10.6B (Rituxan, Avastin, Herceptin, Erbitux, etc.) 03. TNF-a $10.3B (Remicade, Enbrel, Humira) 04. Insulin and analogs $10.0B (many products) 05. Recombinant plasma proteins $4.7B (e.g. NovoSeven) 06. Interferon beta $4.4B (Avonex, Rebif, Beteseron) 07. G-CSF $4.4B (Neupogen, Neulasta) 08* hGH $2.5B (many products) 09. Interferon alpha $2.3B (Pegasys, Peg-Intron) 10. Enzyme replacement $1.7B (e.g. Cerezyme) 11. Antiviral mAb $1.1B (Synagis) 12. FSH $1.0B (Gonal-f, Puregon) Total 2006 sales of these classes: approximately $65B. *Follow-on biologic has been approved. Source: <A HREF="http://www.pipelinereview.com/Top_20_Biologics_by_La_Merie.pdf" target="_blank">http://www.pipelinereview.com/Top_20_Biologics_by_La_Merie.pdf</A>